Soligenix, Inc. (SNGX)
| Market Cap | 51.95M |
| Revenue (ttm) | 2.72M |
| Net Income (ttm) | -15.02M |
| Shares Out | 29.57M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $1.65 |
| Previous Close | $1.68 |
| Change ($) | -0.03 |
| Change (%) | -1.79% |
| Day's Open | 1.65 |
| Day's Range | 1.57 - 1.71 |
| Day's Volume | 1,291,044 |
| 52-Week Range | 1.21 - 3.20 |
New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (...
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commerc...
PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...
New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatm...
PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...
PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
New York, New York--(Newsfile Corp. - December 9, 2020) - The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1...
PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
PRINCETON, N.J., Nov. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 ...
PRINCETON, N.J., Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...
PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Aug. 27, 2020 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc.
Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive Valuation
PRINCETON, N.J., July 20, 2020 /PRNewswire/ -- Soligenix, Inc.
Soligenix (NASDAQ: SNGX) shares were trading higher on Friday after the company completed enrollment in its Phase 3 clinical trial of SGX942 for the treatment of oral mucositis.
PRINCETON, N.J., June 22, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...
PRINCETON, N.J., June 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...
PRINCETON, N.J., May 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...
Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity
Shares of rare disease biopharma Soligenix, Inc. (NASDAQ: SNGX) were spiking higher Thursday after the company announced a coronavirus-related licensing agreement.
Soligenix: Two Phase-3 Clinical Trials - Results By June 2020
About SNGX
Soligenix, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also... [Read more...]
| Industry Biotechnology | IPO Date Jun 15, 1987 |
| CEO Christopher Schaber | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol SNGX |
Financial Performance
In 2019, Soligenix's revenue was $4.63 million, a decrease of -11.67% compared to the previous year's $5.24 million. Losses were -$9.36 million, 5.12% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Soligenix stock is "Buy." The 12-month stock price forecast is 3.85, which is an increase of 133.33% from the latest price.